A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Multiple MyelomaNew Diagnosis Tumor
Interventions
DRUG

Carfilzomib

"* 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."

DRUG

Lenalidomide

\- 25 mg orally on days 1-21 of each cycle.

DRUG

Dexamethasone

"\- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."

Trial Locations (40)

Unknown

"AO SS. Antonio e Biagio", Alessandria

AOU Ospedali Riuniti Umberto I, Ancona

Ospedale Mazzoni, Ascoli Piceno

Policlinico di Bari, Bari

Ospedali Riuniti, Bergamo

Azienda Sanitaria di Bolzano - Ospedale Lorenz B:Ohler, Bolzano

A.O. Spedali Civili di Brescia, Brescia

"Ospedale A. Businco", Cagliari

Istituto per la Cura e la RIcerca del Cancro di Candiolo, Candiolo

Ospedale Civico S. Croce e Carle, Cuneo

AOU Careggi, Florence

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola

Azienda Ospedaliera Papardo, Messina

Policlinico Universitario di Messina, Messina

ASST Grande Ospedale Metropolitano Niguarda, Milan

Istituto Europeo Oncologico, Milan

Istituto Nazionale Tumori, Milan

Ospedale Maggiore Policlinico di Milano, Milan

Università Federico II-Policlinico, Napoli

Ospedale Maggiore, Novara

AO San Luigi Gonzaga, Orbassano

AO di Padova, Padua

AO Cervello, Palermo

Ospedale S. Maria della Misericordia, Perugia

Ospedale Santa Maria delle Croci, Ravenna

AO Bianchi Melacrino Morelli, Reggio Calabria

Ausl-Irccs, Reggio Emilia

Ospedale Infermi, Rimini

Ospedale Oncologico Regionale, Rionero in Vulture

ASL Roma 1, Roma

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma

Ospedale S. Eugenio - Università Tor Vergata, Roma

Ospedale San Camillo Forlanini, Roma

Policlinico Umberto I - Università La Sapienza, Roma

Istituto Clinico Humanitas, Rozzano

IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo

AO S. Maria, Terni

AOU Città della Salute e della Scienza di Torino - PO Molinette - Ematologia U, Torino

AOU Città della Salute e della Scienza di Torino - PO Molinette, Torino

Policlinico Universitario di Udine, Udine

All Listed Sponsors
lead

Fondazione EMN Italy Onlus

OTHER

NCT04096066 - A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | Biotech Hunter | Biotech Hunter